The modified intent to treat (mITT) phase III results with Alcobra Ltd.'s non-stimulant metadoxine extended release (MDX) for attention deficit hyperactivity disorder (ADHD) in adults gave investors the jitters, but they may have been distracted from the real meaning of top-line data by the exclusion of four high responders to placebo.